Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab in Chronic Primary Immune Thrombocytopenia
NCT06722235Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Feb 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of mezagitamab in immune thrombocytopenic purpura (ITP), sponsored by Takeda. Started Feb 2025; status: recruiting.
02
Drugs
mezagitamab
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT06722235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722235.